ClinicalTrials.gg
Not yet recruitingNCT07757659Updated Aug 11, 2026

Bridging Study of XKH001 in Healthy Adult Caucasian Participants

A Phase 1 interventional study of XKH001 Injection and XKH001 Placebo Injection in Healthy Adult, sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase Id, randomised, double-blind, placebo-controlled, multiple-dose, bridging study conducted at a single Phase I clinical research unit in Australia. The study is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of XKH001 following repeated subcutaneous administration in healthy adult Caucasian participants, and to provide an ethnic-bridging pharmacokinetic comparison with the prior Phase I dataset in Chinese participants, required for XKH001's global development programme.

Read the detailed description

The study will consist of two cohorts of healthy adult Caucasian participants. Cohort 1 will receive XKH001 300 mg subcutaneously once every 4 weeks (Q4W) on Day 1, Day 29, and Day 57... Cohort 2 will receive XKH001 600 mg subcutaneously Q4W on Day 1, Day 29, and Day 57. Dosing will be initiated sequentially, with Cohort 1 (300 mg) dosed first, followed by Cohort 2 (600 mg). Dosing in Cohort 2 will not commence earlier than 21 days after the first participant in Cohort 1 receives the first dose and may proceed only following joint review of the available Cohort 1 safety data and unanimous agreement by the Sponsor's medical representative, the Medical Monitor, and the Principal Investigator A total of 16 healthy adult Caucasian participants will be enrolled in the study, with 8 participants per cohort. Within each cohort, participants will be randomised in a 3:1 ratio (6 active drug XKH001; 2 placebo) in a double-blind manner. Randomisation will be performed using a cohort-specific block randomisation schedule to maintain allocation concealment and treatment balance within each cohort. Enrolment will not be stratified by sex; however, at least 3 female participants will be enrolled in each cohort to ensure adequate female representation and to ensure that at least 1 female participant receives the investigational drug.

02

Conditions studied

  • Healthy Adult
03

In context

Lead sponsor

Zhejiang Kanova Biopharmaceutical Co., LTD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy participants who voluntarily provide written and can comply with all study procedures according to the protocol.
  2. Male or female participants of Caucasian ethnicity(both biological parents and all four grandparents of Caucasian origin), 18-65 years of age (inclusive).
  3. (BMI) between 18.0-32.0 kg/m² (inclusive).
  4. Vital signs, physical examination, clinical laboratory tests, and 12-lead (ECG) within normal limits or considered not by the investigator, with ≤450 ms.
  5. No use of prescription or over-the-counter medications within 4 weeks prior to first dosing.
  6. Participants must meet the sex- and reproductive-status-specific and gamete-donation requirements specified in Appendix 2. Where contraception is required, the participant must agree to use the protocol-specified established effective contraception from the time of signing the informed consent form until 7 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Any disease within 5 years that could affect participation (gastrointestinal, renal, hepatic, pulmonary, neurology, Haematology, endocrine, oncology, metabolic, psychiatric, or cerebrovascular).
  3. History of disease, known hereditary immunodeficiency, or recurrent infections suggesting immunodeficiency.
  4. Active infection requiring hospitalisation or IV antibiotics within 3 months, or clinically symptomatic bacterial, viral, or fungal infection within 4 weeks prior to first dosing.
  5. Active or latent tuberculosis infection.
  6. positive, antibody positive, syphilis antibody positive, or antigen/antibody positive.
  7. Live or attenuated vaccine within 4 weeks prior to dosing or planned during trial.
  8. Participation in any clinical trial within 3 months or 5 half-lives of the drug (whichever is longer) prior to dosing.
  9. History of allergy to the investigational drug, any formulation component, or protein-based drugs.
  10. Alcohol consumption >14 units/week within 6 weeks prior to screening, or alcohol-containing products within 1 day before dosing (1 unit = 8 g or 10 mL of pure alcohol).
  11. Drug abuse or illicit substance use within 5 years, or positive urine drug screen(A positive cotinine result alone is not exclusionary).
  12. Smoking history (>5 cigarettes/day) within 3 months prior to screening.
  13. Blood donation or loss >450 mL within 8 weeks, or >200 mL blood donation or >300 mL blood loss within 1 month.
  14. Unsuitable venous access or intolerance of venipuncture.
  15. Prior exposure to any anti-IL-25 therapeutic agent, including XKH001 or any other investigational or approved therapeutic agent targeting IL-25.
  16. Any other reason deemed unsuitable by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (estimated)

Study arms

  • Active comparator
    Cohort 1

    Cohort 1 will receive 300 mg XKH001 Injection or XKH001 Placebo Injection

    Drug: XKH001 Injection · Drug: XKH001 Placebo Injection

  • Active comparator
    Cohort 2

    Cohort 2 will receive 600 mg XKH001 Injection or XKH001 Placebo Injection

    Drug: XKH001 Injection · Drug: XKH001 Placebo Injection

Interventions

  • XKH001, developed by Zhejiang Kanova Biopharmaceutical Co., Ltd., is a recombinant anti-IL-25 humanized IgG1 monoclonal antibody (mAb) composed of two identical light chains and two identical heavy chains linked by disulfide bonds. Each light chain consists of 215 amino acids, and each heavy chain consists of 455 amino acids, for a total of 1340 amino acids.

    Also known as: XKH001

  • DrugXKH001 Placebo Injection

    Placebo;

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Primary Outcome 1

    Maximum observed serum concentration at steady state (Cmax,ss)

    Time frame: Day 1, Day 29, and Day 57

  2. Primary Outcome 2

    Minimum observed serum concentration at steady state (Cmin,ss)

    Time frame: Day 1, Day 29, and Day 57

  3. Primary Outcome 3

    Average serum concentration at steady state (Cavg,ss)

    Time frame: Day 1, Day 29, and Day 57

  4. Primary Outcome 4

    Area under the serum concentration-time curve from time zero to the last quantifiable concentration at steady state (AUC0-t,ss)

    Time frame: Day 1, Day 29, and Day 57

  5. Primary Outcome 5

    Area under the serum concentration-time curve from time zero to the theoretical infinite time at steady state (AUC0-inf,ss)

    Time frame: Day 1, Day 29, and Day 57

  6. Primary Outcome 6

    Area under the serum concentration-time curve over one dosing interval at steady state (AUCtau)

    Time frame: Day 1, Day 29, and Day 57

  7. Primary Outcome 7

    Time to maximum observed serum concentration at steady state (tmax,ss)

    Time frame: Day 1, Day 29, and Day 57

  8. Primary Outcome 8

    Terminal elimination half-life at steady state (t½,ss)

    Time frame: Day 1, Day 29, and Day 57

  9. Primary Outcome 9

    Mean residence time at steady state (MRTss)

    Time frame: Day 1, Day 29, and Day 57

  10. Primary Outcome 10

    Terminal elimination rate constant (λz,ss)

    Time frame: Day 1, Day 29, and Day 57

  11. Primary Outcome 11

    Percent of extrapolated area under the curve (%AUCex)

    Time frame: Day 1, Day 29, and Day 57

  12. Primary Outcome 12

    Accumulation ratio based on Cmax and AUC (Rac)

    Time frame: Day 1, Day 29, and Day 57

  13. Primary Outcome 13

    Apparent clearance at steady state (CLss/F)

    Time frame: Day 1, Day 29, and Day 57

  14. Primary Outcome 14

    Apparent volume of distribution at steady state (Vz,ss/F)

    Time frame: Day 1, Day 29, and Day 57

  15. Primary Outcome 15

    Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent adverse events (TEAEs)

    Time frame: first dose administration through Day 169

  16. Primary Outcome 16

    Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent serious adverse events (SAEs)

    Time frame: first dose administration through Day 169

  17. Primary Outcome 17

    Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent adverse drug reactions (ADRs)

    Time frame: first dose administration through Day 169

  18. Primary Outcome 18

    Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent suspected unexpected serious adverse reactions (SUSARs)

    Time frame: first dose administration through Day 169

  19. Primary Outcome 19

    Incidence and severity of local injection-site reactions following subcutaneous administration of XKH001 or placebo

    Time frame: first dose administration through Day 169

Secondary outcomes

  1. Secondary Outcome 1

    Incidence of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples

    Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.

  2. Secondary Outcome 2

    Prevalence of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples

    Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.

  3. Secondary Outcome 3

    Characterisation of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples

    Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.

Other outcomes

  1. Other Pre-specified Outcomes1

    Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including eosinophils

    Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.

  2. Other Pre-specified Outcomes2

    Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including neutrophils

    Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.

  3. Other Pre-specified Outcomes3

    Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including lymphocytes

    Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.

  4. Other Pre-specified Outcomes4

    Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including monocytes

    Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.

  5. Other Pre-specified Outcomes5

    Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including total IgE.

    Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.

07

Study locations

1 site
  • Q-Pharm Pty Limited (also known as Nucleus Network Brisbane)
    Melbourne, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 11, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07757659
Lead sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Jiangguo You
Contact
jianguo.you@kanovabiopharma.com
010-82176552
Yaxin Li
Contact
yaxin.li@kanovabiopharma.com
010-82176552

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XKH001

Start the discussion